

Phospholipid Compounds of Physiological Importance

Biochemistry Team 431

Team Leaders:

Lama Mokhlis

Osamah Al-jarallah

Team Members:

Dalal Fatani

Abdulaziz Al-shamlan

Anood Alasiri

Abdullah Al-Mazyad

Noha Khalil

Turki Al-otaibi

Reem AlMansour

Khalid Al-khamis

Hadeel Helmi

AlHanouf Alomran

PHOSPHOLIPID COMPOUNDS OF PHYSIOLOGICAL IMPORTANCE

Most importantly : SURFACTANT

Remember: **LIPID** a heterogenous group with relatively weak-insoluble “soluble in NONPOLAR”
Except ketone bodies.

SIMPLE LIPIDS:

Fatty acids
Ketone bodies
Triacylglycerol
Cholestrol

COMPLEX LIPIDS:

Phospholipids
Lipoproteins
Glycolipids

STRUCTURE OF PHOSPHOLIPIDS

Back bone made up of either glycerol or sphingosine (determines the type, glycerol- or sphingo-phospholipid) + fatty acid branches + phosphate group with variable base attachment (determines the phospholipid)

FUNCTIONS OF PHOSPHOLIPIDS

Membrane-bound

****Structural:** lipids of cell membrane (bilayer)
(Amphipathic → hydrophobic in the center
Hydrophilic inward and outward)
Anchoring: attaching proteins to membrane
Signaling: source of secondary messengers
Ex: IP3 and DAG
Specific functions: Ex: **myelin sheaths**
Insulator & speed up nerve impulse

Non-membrane-bound

****Lung Surfactant:** re-inflation of alveoli
by air
Detergent effect: (washing effect)
essential component of BILE:
1. solubilize cholesterol → prevent gallstone
2. emulsify lipids and help digest them
emulsify: blend
Structural: Coat of lipoprotein (outer)

PHOSPHOLIPIDS BASED ON THEIR STRUCTURES

1. GLYCEROPHOSPHOLIPIDS: glycerol + phospholipid

Parent compound: PHOSPHATIDIC ACID

A) **Phosphatidylcholine (lecithin)** → surfactant “dipalmitoylecithin”
“dipalmitophosphatidylcholine”

**** Major lipid component of lung surfactant**

-Synthesis & secretion: by granular pneumocytes (type II)

SURFACTANT:

Is made of dipalmitoylecithin (65%) + other phospholipids, cholesterol & protein (35%)

Function: Decreases surface tension of fluid lining of alveoli → decreases pressure against inflation by air → PREVENT ALVEOLAR COLLAPSE = “atelectasis”

CONGENITAL RESPIRATORY DISTRESS SYNDROME (RDS)

Insufficient production of lung surfactant <in pre-term babies> → causing neonatal death

Prenatal diagnosis by:

Lecithin/sphingomyelin ration (L/S) in amniotic fluid

Ratio= **2 or above** → lung maturity and no RDS [normal: shift from sphingomyelin to lecithin synthesis by pneumocytes by 32nd week of gestation → **[L higher than S]**

Lower than 2 → RDS [sphingomyelin is higher]

Prevention: glucocorticoids to pregnant mother (with low L/S ratio) shortly before delivery

Treatment: intratracheal administration of surfactant to pre-term infants with RDS

(airway catheter -tubular instrument- in the trachea to assist breathing)

B) **Phosphatidylinositol 4,5 bisphosphate** [PIP₂ system]

**Is broken down by the enzyme: phospholipase C to give the 2nd messengers:

1. DAG "Diacylglycerol"
2. IP₃ "inositol triphosphate"

Signal: hormones or neurotransmitters

Ex: ACh

Anti-diuretic hormone (V₁ receptor)

Catecholamines "E.g. epinephrine, norepinephrine and dopamine" (α_1 actions)

Receptor: G-Protein coupled receptor

Effects: activation of phospholipase C → yielding of DAG + IP₃ (Ca²⁺ release from endoplasmic reticulum) → activate protein kinase C

Response: phosphorylation (activation or inactivation) of cellular proteins and response to hormones

PROTEIN ANCHORING: attach proteins to membranes via

CARBOHYDRATE-PHOSPHATIDYLINOSITOL BRIDGE

Ex: 1. **Alkaline phosphatase** (attaches to surface of small intestines)

2. **Acetylcholine esterase** (attaches to postsynaptic membrane)

**these proteins can be cleaved (removed) from their attachment to membranes by Phospholipase C.

2. SPHINGO-PHOSPHOLIPIDS: <<myelin sheath>> sphingosine + phospholipid

**Parent compound: Ceramide

MYELIN SHEATH

80% lipid (glycolipids and sphingomyelin) + 20% Protein

Function: insulates nerve axon → prevent signal leakage

speed up transmission of impulses

LIPOPROTEIN STRUCTURE

Outer part [coat]: - apoprotein/apolipoprotein <<AMPHIPHATHIC PHOSPHOLIPIDS>>

-Free cholesterol: hydrophilic (relatively) → allow lipid transport in aqueous plasma

Inner part [core]:

According to type of lipoproteins

Different lipid components in various combinations

PHOSPHOLIPASE FAMILY

Phospholipases are specific to the type of phospholipid it breaks down

Glycerophospholipids: A1, A2, C & D* (found in mammalian tissue, except D> in plants only)

Sphingophospholipids: lysosomal phospholipase & sphingomyelinase

TYPES:

1. Phospholipase A₁:

Found in many mammalian tissue

Breaks the bond between the 1st fatty acid and the 1st C of the backbone

2. Phospholipase A₂:

Found in many mammalian tissues, pancreatic juice and snake & bee venom

Breaks down the 2nd fatty acid of the backbone

Acts on phosphatidylinositol to release arachidonic acid, which is the precursor for prostaglandins

Pancreatic secretions [digestive enzyme] is a proenzyme, hence requires activation by trypsin. Bile salts are also needed for activity.

Is inhibited by glucocorticoids (ex: cortisol)

3. Phospholipase C:

Found in liver lysosomes and some bacterial toxins

Some are membrane bound and are activated by the PIP₂ system to produce the second messengers IP₃ and DAG

Breaks down bond between backbone and phosphate group

4. Phospholipase D:

Found primarily in plants [non-mammalian]

Breaks the base off the phosphate group

- Sphingomyelinase breaks down sphingomyelin into ceramide and phosphocholine
-

FUNCTIONS OF PHOSPHOLIPASES

Degradation of phospholipids:

- Production of second messengers (type C)
- Digestion by pancreatic juices (type A₂)
- Degradation of membranes by pathogenic bacteria to spread infection (type C)

Remodeling of phospholipids:

Specific phospholipases that remove fatty acids from the backbone to yield another type of phospholipid

Fatty acyl CoA transferase replace fatty acid by an alternative fatty acid

EX: Binding of 2 palmitic acids in dipalmitoylphosphatidylcholine (**DPPC-Lecithin**)

Binding of arachidonic to carbon # 2 of PI or PC

Questions

Degree of relevance: * * * * *

1- An infant, born at 28 weeks of gestation, rapidly gave evidence of respiratory distress. Lap and x-ray results supported the diagnosis of infant respiratory distress syndrome (RDS). Which of the following statements about this syndrome is true?

- A. It is unrelated to the baby's premature birth.
- B. It is a consequence of too few Type II pneumocytes (granular pneumocytes).
- C. The lecithin/sphingomyelin ratio in the amniotic fluid is likely to be greater than two.
- D. The concentration of dipalmitoylphosphatidylcholine in the amniotic fluid would be expected to be lower than that of a full-term baby.
- E. RDS is an easily treated disorder with low motility.

Degree of relevance: * * *

2- Aspirin-induced asthma (AIA) is a severe reaction to nonsteroidal anti-inflammatory drugs (NSAIDs) characterized by bronchoconstriction 30 minutes to several hours after ingestion. It is seen in as many as 20% of adults. Which of the following statements best explains the symptoms seen in patients with AIA?

- A. NSAIDs inhibit the activity of Cystic fibrosis transmembrane conductance regulator (CFTR protein) resulting in thickened secretion that block airways.
- B. NSAIDs inhibit COX but not lipoxygenase, resulting in the flow of arachidonic acid to leukotriene synthesis.
- C. NSAIDs activate the COX activity of PGH synthase, resulting in increased synthesis of prostaglandins that promote vasodilation.
- D. NSAIDs activate phospholipases, resulting in decreased amounts of dipalmytoylphosphatidylcholine and alveolar collapse (atelectasis).

Correct Answers:

1- D.

DPPC (surfactant) is reduced in baby with RDS

2- B.

NSAIDs inhibit COX but not lipoxygenase, so any arachidonic acid available is used for the synthesis of bronchoconstricting-leukotrienes. NSAIDs have no effect on CFTR protein, defect in which are the cause of cystic fibrosis.